Prot #42160443PAI3002: Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects with Signs and Symptoms of Osteoarthritis of the Hip or Knee

Project: Research project

Project Details

Effective start/end date7/22/157/22/18


  • inVentiv Health Clinical (Prot #42160443PAI3002 // Prot #42160443PAI3002)
  • Janssen Research & Development, LLC (Prot #42160443PAI3002 // Prot #42160443PAI3002)